country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-W716673

Copy Link Print Information

Ftivazide

(別名: Phthivazide)

カスタマーレビュー

Based on 1 Customer Validation

Ftivazide has anti-tuberculosis activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.9%
CAS 番号: 149-17-7
分子式: C₁₄H₁₃N₃O₃
分子量:271.27

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ftivazide 構造式

CAS 番号: 149-17-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Ftivazide has anti-tuberculosis activity^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
HEL	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HEL	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HEL	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HEL	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HeLa	EC₅₀	>20 μg/mL Compound: 2	Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HeLa	EC₅₀	>20 μg/mL Compound: 2	Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HeLa	EC₅₀	>20 μg/mL Compound: 2	Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	CC₅₀	>=89 μg/mL Compound: 2	Cytotoxicity against Homo sapiens (human) MT4 cells Cytotoxicity against Homo sapiens (human) MT4 cells	10.1007/s00044-011-9662-9
MT4	EC₅₀	>89 μg/mL Compound: 2	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	EC₅₀	>89 μg/mL Compound: 2	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>100 μg/mL Compound: 2	Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9

化学情報

CAS 番号 149-17-7
性状 Solid
分子量 271.27
分子式 C₁₄H₁₃N₃O₃
Color White to off-white
SMILES

O=C(C1=CC=NC=C1)N/N=C/C2=CC(OC)=C(C=C2)O
別名

Phthivazide
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (264 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Dmitriy Khrustalev, et al. Synthesis of anti-tuberculosis drugs in a microwave flow reactor. Materials Today: Proceedings, 2023, 81: 1186-1191.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Ftivazide

High-Throughput Bioactive Compound Library

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Ftivazide 関連分類

HY-W716673 関連分類